Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

3,970 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hengli® Chinese Botulinum Toxin Type A for Treatment of Patients With Overactive Bladder: A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial.
Liao L, Liu Q, Cong H, Xu Z, Li E, Weng Z, Jiang H, Liu B, Huang X, Xia S, Wen W, Wu J, Shi G, Wang Y, Li P, Yu Y, Fang Z, Zheng J, Tian Y, Shang D, Li H, Huang Z, Zhou L, Xiao Y, Zhang Y, Wang J, Zhang X, Zhang P, Wang D, Zhang X, Xie K, Wang B, Ma L, Tian X, Chen L, Dong J. Liao L, et al. Among authors: li e, li h, li p. Front Pharmacol. 2022 Feb 18;13:840695. doi: 10.3389/fphar.2022.840695. eCollection 2022. Front Pharmacol. 2022. PMID: 35250586 Free PMC article.
3,970 results